Last reviewed · How we verify
NCT03055208: Gamma-GBM
Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed Glioblastoma
NA trial testing gamma knife radiosurgery (15 Gy to 50% isodose) in Glioblastoma in 50 participants. Suspended.
30 March 2020
Quick facts
| Lead sponsor | Universitätsmedizin Mannheim |
|---|---|
| Phase | NA |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 8 February 2017 |
| Primary completion | 30 March 2020 |
| Estimated completion | 9 May 2023 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- gamma knife radiosurgery (15 Gy to 50% isodose)
Conditions studied
- Glioblastoma — all drugs for Glioblastoma →
Sponsor
Universitätsmedizin Mannheim — full company profile →
Who can join
18 and older, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Gamma GBM is a single-arm phase II trial that prospectively measures the progression-free survival time after addition of an early gamma knife boost to areas of residual tumor to standard-of-care (surgery, chemo-radiotherapy, chemotherapy).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature.
Waqar M, Trifiletti DM, McBain C, O'Connor J, et al · · 2022 · cited 27× · PMID 35119629 · DOI 10.1007/s11912-021-01157-0
Verify or expand the search:
- PubMed search for NCT03055208
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glioblastoma
Currently open trials in the same condition.
- NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
- NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Universitätsmedizin Mannheim trials
Trials by the same sponsor.
- NCT06416319 — Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct) · NA · recruiting
- NCT04534998 — Robotic-assisted vs. Open Partial Nephrectomy · Phase 2 · unknown
- NCT05575856 — Cardiogenic Shock Registry Mannheim · unknown
- NCT04146701 — Metabolomics and Microbiomics in Cardiovascular Diseases · unknown
- NCT04533633 — German Epicardial Collateral CTO Registry · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03055208 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitätsmedizin Mannheim
- Last refreshed: 11 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03055208.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing